 |
Cleveland Clinic Researchers Discover Similarities Between Next-Generation Prostate Cancer Drugs
Next-generation anti-androgens are potent drugs that work by cutting off the prostate tumor's supply of androgens (male hormones), which fuel prostate cancer. The drugs, used in patients whose cancer has become resistant to hormone deprivation therapy, have been shown to improve survival in men with metastatic disease. Unfortunately, prostate tumors eventually become resistant to these drugs, highlighting the need for new therapies.
 |
|
|
Nima Sharifi
|
"Despite an array of improved treatment options that have become available over the past decade, prostate cancer remains the second leading cause of cancer mortality in men in the United States. There are few therapeutic options for men whose cancer has become resistant to all therapies," said
Nima Sharifi, MD, lead author on the study and co-Leader of the GU Malignancies Program, Case Comprehensive Cancer Center. "Our goal is to improve the use and role of these existing drugs and hopefully design new therapies that work better and longer."
more>
|
Steinmetz Inducted into Elite Medical and Biological Engineering College of Fellows
|
|
|
Nicole Steinmetz
|
Nicole Steinmetz, PhD, Case Comprehensive Cancer Center,
Associate Professor of Biomedical Engineering, CWRU, was
indicted into the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. Dr. Steinmetz was nominated, reviewed, and elected by peers and members of the College of Fellows for outstanding contributions to advancement of plant virus-based nanomaterials for diagnostics, drug-delivery and immunotherapy in cancer, cardiovascular disease, and others.
The College of Fellows is comprised of the top two percent of medical and biological engineers in the country. The most accomplished and distinguished engineering and medical school chairs, research directors, professors, innovators, and successful entrepreneurs, comprise the College of Fellows.
|
Spina Recognized with AACR Scholar in Training Award
|
|
|
Raffaella Spina
|
Raffaella Spina, PhD
received a Scholar in Training Award from the American Association for Cancer Research (AACR). These awards enable the participation of meritorious early-career scientists at the Annual Meeting 2017. Spina is a postdoctoral fellow in the lab of Case CCC member Dr. Eli Bar in the Department of Neurological Surgery at CWRU SOM and University Hospitals Cleveland Medical Center.
|
Cultural Competency Series Name Change
The Case CCC Minority Accrual Committee (MAC) has renamed the "Cultural Competency Series" as the "Cultural Inclusion and Awareness Series." This new name allows the Committee to broaden the series' scope and post information which will have more research focus.
|
Case CCC Annual Scientific Retreat
Jul 20 | Tinkham Veale, CWRU campus
The
Case Comprehensive Cancer Center Annual Scientific Retreat will be held July 20, 2017 at the Tinkham Veale University Center on CWRU campus. We will kick-off the retreat in the afternoon with a keynote presentation from Ramon Parsons, MD, PhD, Professor and Chairman, Oncological Sciences, Icahn School of Medicine at Mount Sinai, followed by a Director's Overview by Case CCC Director Stan Gerson, MD.
A cocktail reception with heavy hors d'oeuvres will follow the presentations, allowing you the chance to network with your colleagues.
Call for Abstracts
We will once again have poster presentations by students, postdocs and fellows. Poster judging be conducted prior to the start of the program (2:30-4:30p), and the poster presentation session will run concurrently with the cocktail reception (6-8p). This is your chance to view the incredible research being conducted by the next generation of cancer researchers. Please
encourage your trainees, fellows and students to submit an abstract.
Please plan to set aside the time to participate in this year's retreat. Register early, and we will see you there!
|
Mesenchymal Stem Cell (MSC) Conference
 Aug 14-16 | Marriott Key Center, Downtown
MSC 2017 will offer a forum for cutting-edge breakthroughs in translational stem cell therapy and regenerative medicine.
MSC 2017 will feature:
- Invited lectures by domestic & international thought-leaders
- Pre-conference workshop for young investigators
- Stem cell tourism panel discussion
- Short talks (selected from abstracts)
- Poster session & networking reception
- Innovative Start-up award
- Best poster awards
|
Genomic Medicine Institute 5th Annual Genetics Education Symposium -
 Sep 7, 2017 | InterContinental Hotel
Registration is open for the Genomic Medicine Institute's 5th Annual Genetics Education Symposium. This year's
program promises an engaging day with an emphasis on advances in the diagnosis and management of genetic conditions as they pertain to women's health. Other topics include ethical dilemmas unique to the practice of genetics in this arena, current and emerging trends in genetic test reimbursement, and innovative patient appointment options such as newly introduced telegenetics and shared medical appointments.
|
International Cancer Education Conference
Sep 13-15 | Westin Cleveland Downtown
 The International Cancer Education Conference is the only meeting in North America totally dedicated to cancer education - ranging from medical professionals to patients and community education. Register to attend this meeting of national and international specialists in cancer education, survivorship and palliative care focused on advocacy, scientific investigation, program and curriculum development, skill training, and evaluation. National leaders will be presenting special programs on grant writing (National Cancer Institute), cancer and the elderly (Cancer and Aging Research Group), surgical oncology (American College of Surgeons), plus dedicated mentoring opportunities will be available to present to content experts.
|
Graft versus Host Disease National Symposium
Oct 13 | Grand Event Center - Columbus
 The GvHD National Conference focuses on cutting edge research and new treatments, consists of two tracks: one for physicians and other health care professionals, and one for BMT survivors, their families and their caregivers. The Meredith A. Cowden Foundation in collaboration with the Case CCC, UH Seidman Cancer Center, and Cleveland Clinic Taussig Cancer Institute, created the National GvHD Health Symposium in 2010 to raise awareness about Graft vs. Host Disease (GvHD), to promote research to further our understanding of its cause, and to review cutting edge approaches to prevention and treatment. Over 1,200 people have attended this event, which provides an opportunity for attendees to interact with some of the world's leading authorities on GvHD, a complication that affects over 60% of bone marrow transplant patients. This year we are excited to team up with the The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute as hosts of the 2017 symposium! CME credits will be offered. Register today!
|
Cleveland Clinic 2017 Medical Innovation Summit
Oct 23-25 | Huntington Convention Center
Cleveland Clinic's
Medical Innovation Summit
will bring together more than 2,250 of the brightest leaders from around the world to downtown Cleveland to discuss transformative technologies that will deliver on the powerful promise of genomics and precision medicine.
Now in its 15
th year, the annual Medical Innovation Summit is organized by
Cleveland Clinic Innovations, the development and commercialization arm of Cleveland Clinic, which has developed 77 spin-off companies since it was founded in 2000.
The
agenda includes thought-provoking panels, as well as lively 1-on-1 discussions with top healthcare, industry and biotech leaders. Topics include: next-generation genomic sequencing; the gene therapy and gene editing markets; artificial intelligence and decision support technologies; customized implants and robotics; the investors' perspective on precision medicine; and reimbursement strategies for genomic innovation.
The 2017 Medical Innovation Summit will be held at the Huntington Convention Center in downtown Cleveland.
Registration is now open
.
|
Azacitidine-based combination may improve response rate in chronic myelomonocytic leukemia
Helio/HemOnc Today - Jun 21, 2017
Mikkael A. Sekeres, MD, MS, Case Comprehensive Cancer Center, director of the leukemia program at Cleveland Clinic Taussig Cancer Institute, and colleagues conducted a phase 2 analysis to determine if azacitidine in combination with lenalidomide or vorinostat would improve response rates to warrant an OS analysis of one of the combinations in a phase 3 trial.
|
The New War on (Overpriced) Drugs
Wired - Jun 10, 2017
Unless you have multiple myeloma, a rare and vicious cancer of the blood, chances are you haven't heard of Revlimid. The immunomodulatory drug slows the growth of new blood vessels, and it's a product of the kind of ingenuity and daring that once made the pharmaceutical industry among the most respected in America. It's also a handy stand-in for everything that's wrong with the business today...Several promising new myeloma drugs have recently been released, including a new and improved follow-up treatment to Revlimid called Pomalyst. Each drug costs more than $150,000, and Pomalyst comes in over $195,000. "This is not a sustainable model," says Brian Bolwell, chairman of the Taussig Cancer Institute at the Cleveland Clinic, Case Comprehensive Cancer Center.
|
2018 Szent-Györgyi Prize
for Progress in Cancer Research
Deadline: Sep 30
The
Szent-Györgyi Prize for Progress in Cancer Research was established to honor an outstanding researcher whose scientific achievements have expanded our understanding of cancer and cancer causation; whose vision has moved cancer research in new directions; and whose discoveries have resulted in notable advances in cancer prevention, diagnosis, or treatment.
Nominations for the Prize may be made by individuals from the research community, industry, government, or other organizations who are sufficiently familiar with the research accomplishments and contributions of the nominee. Self-nominations will not be accepted. Candidates must have made an original discovery or breakthrough in scientific understanding that has led to better prevention, earlier diagnosis, or new treatments for patients with cancer.
|
NIH BULLETIN- Notices and Funding Opportunities
|
|
|
FOLLOW US
|
VELOSANO 2017
Jul 21-23, 2017
Ride with Us!
We have
97 riders on our team - can we hit 100?!
Cheer with Us!
Thank you to our Team Sponsors!
Spangenberg Shibley & Liber LLP
Flight Options/FlexJet
Taft Stettinius & Hollister LLP
Majic Family Fund
New Belgium
TOLI
CWRU School of Medicine
CWRU School of Engineering
|
EVENTS
|
|
Wed, Jun 28
ASCO Review: Highlights of the National Meeting
8a InterContinental Hotel
Registration
Hem/Onc Division Conf
Immunology Invited Speaker Seminar Series
John A. Cidlowski, PhD National Institute of Environmental Health Sciences, National Institutes of Health
"Cell Type Specific Actions of Glucocorticoids in Health and Diseases"
12p NC1-202
|
|
Thur, Jun 29
Developmental Therapeutics Journal Club
9a R4-013 |
|
Fri, Jun 30
TCI Grand Rounds
Jessica Geiger, MD; Aaron Gerds, MD; Nathan Pennell, MD
Cleveland Clinic
"ASCO Poster and Oral Presentations"
8a R3/002-003 |
|
Wed, Jul 5
Hem/Onc Grand Rounds
8a Lerner B-151 |
|
Thur, Jul 6
Developmental Therapeutics Journal Club
9a R4-013 |
|
Fri, Jul 7
TCI Grand Rounds
8a R3/002-003 |
ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
AACI Clinical Research Initiative Meeting
Jul 12-13, 2017
Loews Chicago O'Hare Hotel
Details
Mesenchymal Stem Cell Conference 2017
Aug 14-16, 2017
Marriott Key Center
International Cancer Education Conference
Sep 13-15, 2017
Westin Cleveland Downtown
GvHD National Symposium
Oct 13, 2017
Grand Event Center, Columbus, OH
|
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Pre-Application: Jun 28, 2017
Application: Sep 27, 2017
Pre-Application: Jun 28, 2017
Application: Sep 27, 2017
Pre-Application: Jun 28, 2017
Application: Sep 27, 2017
Pre-Application: Jun 30, 2017
Application: Sep 28, 2017
Pre-Application: Jun 30, 2017
Application: Sep 28, 2017
Deadline: Jul 6, 2017
Deadline: Jul 7, 2017
LOI: Jul 13, 2017
Application: Oct 5, 2017
Pre-Application: Jul 27, 2017
Application: Aug 10, 2017
LOI: Sep 12, 2017
Application: Sep 28, 2017
Pre-Application: Sep 13, 2017
Application: Sep 27, 2017
Deadline: Open
Deadline: Open
Deadline: Open
|
|
|
|
